Who is sponsoring NCT07091266?

NCT07091266 is sponsored by Shiyan City Renmin Hospital.

What drugs are being tested in NCT07091266?

Interventions in NCT07091266: Sacral Neuromodulation (SNM), Hyperbaric Oxygen Therapy (HBOT).

Is NCT07091266 still recruiting?

NCT07091266 is currently completed. Last updated 29 July 2025.

Last reviewed 2025-07-29 · How we verify

NCT07091266

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SNM vs. HBOT for Refractory IC/BPS

Completed NA Last updated 29 July 2025

What this trial tests

NA trial testing Sacral Neuromodulation (SNM) in Interstitial Cystitis/Bladder Pain Syndrome in 88 participants. Completed in 31 December 2022.

Timeline

1 February 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Shiyan City Renmin Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	88
Start date	1 February 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

Sacral Neuromodulation (SNM)
Hyperbaric Oxygen Therapy (HBOT)

Conditions studied

Interstitial Cystitis/Bladder Pain Syndrome — all drugs for Interstitial Cystitis/Bladder Pain Syndrome →
Underactive Bladder — all drugs for Underactive Bladder →

Sponsor

Shiyan City Renmin Hospital

Who can join

18 and older, any sex, with Interstitial Cystitis/Bladder Pain Syndrome or Underactive Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is for people with long-term bladder pain and urinary problems (known as Interstitial Cystitis/Bladder Pain Syndrome or IC/BPS) that have not improved with other treatments. The study compares two different treatments: Sacral Neuromodulation (SNM), which uses an implanted device to send gentle electrical pulses to nerves controlling the bladder, and Hyperbaric Oxygen Therapy (HBOT), where patients breathe pure oxygen in a special chamber. Participants were randomly assigned to one of the two groups to help doctors understand which treatment works better to reduce symptoms and improve quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Shiyan City Renmin Hospital trials

Trials by the same sponsor.

NCT07055035 — Atrial Synchrony Evaluation of Bachmann Bundle Pacing in Sick Sinus Syndrome · NA · completed
NCT07074834 — Metoprolol and Trimetazidine for Coronary Heart Disease With Angina · NA · completed
NCT07126132 — Hpx•apoB Product as a Biomarker for Coronary Artery Disease · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07091266 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shiyan City Renmin Hospital
Last refreshed: 29 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07091266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing